|
| Press Releases |
|
 |
|
| Friday, August 16, 2024 |
|
|
康哲药业（00867）发布2024年中期业绩：营业额和利润环比均稳步提升 |
| 康哲药业发布2024年中期业绩公告，整体营业额和期间利润环比去年下半年稳步提升。2024年上半年实现营收36.11亿元，同比下降21.7%，环比增长6.1%；若全按药品销售收入计算营收42.88亿元，同比下降22.6%，环比增长8.9%；其中，非国采独家产品及创新产品合计销售收入为人民币24.05亿元，占全按药品销售收入计算营业额的56.1%。实现净利润9.03亿元，同比下降52.8%，环比大幅增长92.8%。 more info >> |
|
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
| On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
|
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023 |
| On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. more info >> |
|
| Tuesday, August 6, 2024 |
|
|
康哲药业：甲氨蝶呤注射液增加类风湿关节炎适应症中国NDA获批（更正版） |
| 康哲药业控股有限公司（“本公司”，连同其附属公司统称为“本集团”或“康哲药业”）欣然宣布，甲氨蝶呤注射液（“产品”）增加适应症的上市许可申请（NDA）已于2024年7月30日获得国家药品监督管理局（NMPA）批准。 more info >> |
|
|
康哲藥業：甲氨蝶呤注射液增加類風濕關節炎適應症中國NDA獲批 |
| 康哲藥業控股有限公司（“本公司”，連同其附屬公司統稱為“本集團”或“康哲藥業”）欣然宣佈，甲氨蝶呤注射液（“產品”）增加適應症的上市許可申請（NDA）已於2024年7月30日獲得國家藥品監督管理局（NMPA）批准。 more info >> |
|
| Monday, August 5, 2024 |
|
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
|
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA). more info >> |
|
| Tuesday, July 16, 2024 |
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating |
| In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development. more info >> |
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating |
| In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development. more info >> |
|
| Tuesday, June 25, 2024 |
|
|
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China |
| On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Q2 Metals Intercepts 179.6 Metres of Continuous Spodumene Pegmatite in Large Step-Out at the Cisco Lithium Project in Quebec, Canada
Mar 22, 2025 02:40 HKT/SGT
|
|
|
Raya Lebih Bermakna: Spritzer Sparkling's Raya 2025 Brings Fans Closer to Family and Stars
Mar 22, 2025 01:54 HKT/SGT
|
|
|
China Medical System (00867) Released its 2024 Annual Results: Focusing on Innovation and Specialty Breakthroughs to Reshape Growth Momentum
Mar 21, 2025 23:00 HKT/SGT
|
|
|
Sino Biopharm (1177.HK) Announces 2024 Annual Results
Mar 21, 2025 22:15 HKT/SGT
|
|
|
祖龙娱乐发布2024年全年业绩
Mar 21, 2025 20:49 HKT/SGT
|
|
|
Summit Group Holds Iftar in Singapore for About 200 Migrant Workers, Including Bangladeshis
Mar 21, 2025 19:00 HKT/SGT
|
|
|
中國生物製藥（1177.HK）公佈2024全年業績
Mar 21, 2025 18:21 HKT/SGT
|
|
|
招金礦業（1818.HK）全年業績超預期：淨利潤大幅飆升120.8% 每股盈利增加150%
Mar 21, 2025 17:19 HKT/SGT
|
|
|
The 33rd China International Bicycle Fair 2025 Set to Grandly Open
Mar 21, 2025 17:00 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Receives Additional Orders for Three Methanol-Fueled RORO Cargo Ships
Mar 21, 2025 17:48 JST
|
|
|
Xforce HEV Model Premieres in Thailand
Mar 21, 2025 16:09 JST
|
|
|
Jiangsu Horizon Chain Supermarket, a Supermarket and Convenience Store Chain Store Operator, Announces Its Global Offering and Listing of H Shares on the Main Board of the Hong Kong Stock Exchange
Mar 21, 2025 15:00 HKT/SGT
|
|
|
超市及便利店連鎖運營商 江蘇宏信超市H股全球發售
Mar 21, 2025 14:39 HKT/SGT
|
|
|
三菱重工、特定技術分野の最高峰「技監」と技能の最高峰「範師」を新たに認定
Mar 21, 2025 14:15: JST
|
|
|
超市及便利店连锁运营商 江苏宏信超市H股全球发售
Mar 21, 2025 14:11 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
